Novartis Investor Presentation

2. Launch excellence New Novartis: Our strategy Our focus Our priorities Improved financials > Launch excellence High-value innovation Operational excellence Strengthen foundations Conclusion Abbreviations Recently launched Pluvicto™ and Scemblix® add potential upsides PLUVICTO™ US launch beating internal expectations ☐ Manufacturing issues remediated Permanent A code granted in Jul, effective Oct More than 50% of insured lives covered (across Medicare, Medicaid and private payers) >100 target RLT sites operational Additional Ph3 studies in earlier settings on track (pre-taxane mCRPC and mHSPC) SCEMBLIX' continues strong US uptake (asciminib) 20 mg. 40 mg tablets $31m Q2 sales driven by patients with resistance/intolerance to other TKIs 44% 3L+ new patient share1 16% NBRx share across CML lines of treatment¹ 1L Ph3 study (1L) enrolling ahead of plan EC approval and rollout ongoing across ex- US markets 1. Source: IQVIA Market Sizing "Source of Business", "Product Summary" reports, June 2022 19 Novartis Investor Presentation | September 22, 2022 1 | NOVARTIS | Reimagining Medicine

View entire presentation